Medtronic PLC $MDT Shares Bought by Rowlandmiller & PARTNERS.ADV

Rowlandmiller & PARTNERS.ADV raised its holdings in shares of Medtronic PLC (NYSE:MDT) by 32.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,633 shares of the medical technology company’s stock after buying an additional 5,512 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Medtronic were worth $2,156,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of MDT. 1248 Management LLC acquired a new position in shares of Medtronic during the 1st quarter worth approximately $26,000. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic in the second quarter valued at approximately $27,000. Twin Tree Management LP purchased a new position in Medtronic during the first quarter worth approximately $29,000. Activest Wealth Management lifted its position in Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares in the last quarter. Finally, GFG Capital LLC acquired a new position in Medtronic during the second quarter worth $36,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Trading Up 0.1%

NYSE MDT opened at $99.86 on Monday. The firm’s 50-day moving average is $97.27 and its two-hundred day moving average is $92.96. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock has a market capitalization of $128.02 billion, a P/E ratio of 26.92, a PEG ratio of 2.63 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the business earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a $0.71 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s payout ratio is presently 76.55%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on MDT shares. JPMorgan Chase & Co. raised their target price on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Stifel Nicolaus upped their price objective on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medtronic in a report on Monday, December 8th. Finally, Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $110.44.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.